Dimensional Fund Advisors LP trimmed its position in shares of ProPhase Labs, Inc. (NASDAQ:PRPH) by 6.8% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 146,457 shares of the company’s stock after selling 10,701 shares during the quarter. Dimensional Fund Advisors LP owned approximately 0.85% of ProPhase Labs worth $306,000 as of its most recent SEC filing.

In other news, CFO Robert V. Cuddihy, Jr. sold 358,621 shares of the firm’s stock in a transaction dated Friday, September 29th. The stock was sold at an average price of $2.30, for a total transaction of $824,828.30. Following the completion of the transaction, the chief financial officer now directly owns 132,703 shares in the company, valued at $305,216.90. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Braden Michael Leonard sold 1,695,305 shares of the firm’s stock in a transaction dated Friday, September 29th. The stock was sold at an average price of $2.30, for a total value of $3,899,201.50. The disclosure for this sale can be found here. Insiders have sold 2,423,255 shares of company stock worth $5,573,487 over the last three months. Insiders own 29.60% of the company’s stock.

Shares of ProPhase Labs, Inc. (NASDAQ:PRPH) opened at $2.25 on Thursday. ProPhase Labs, Inc. has a 12 month low of $1.78 and a 12 month high of $2.45. The company has a market capitalization of $27.96, a PE ratio of 2.92 and a beta of 0.18.

ProPhase Labs (NASDAQ:PRPH) last announced its quarterly earnings results on Monday, November 13th. The company reported ($0.05) EPS for the quarter. ProPhase Labs had a net margin of 307.58% and a return on equity of 40.36%. The firm had revenue of $3.04 million for the quarter.

ProPhase Labs declared that its Board of Directors has initiated a share buyback program on Tuesday, August 15th that authorizes the company to buyback 4,000,000 shares. This buyback authorization authorizes the company to purchase shares of its stock through a tender offer. Stock buyback programs are usually a sign that the company’s board of directors believes its shares are undervalued.

Separately, ValuEngine lowered ProPhase Labs from a “hold” rating to a “sell” rating in a research note on Thursday, October 5th.

ILLEGAL ACTIVITY WARNING: This news story was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another domain, it was copied illegally and reposted in violation of U.S. & international copyright & trademark legislation. The legal version of this news story can be read at https://www.thecerbatgem.com/2017/12/07/prophase-labs-inc-prph-shares-sold-by-dimensional-fund-advisors-lp.html.

ProPhase Labs Profile

ProPhase Labs, Inc manufactures, markets and distributes a range of homeopathic and healthcare products. The Company is engaged in the research and development of over-the-counter (OTC) drugs and natural base health products, including supplements, personal care and cosmeceutical products. The Company’s products include TK Supplements and ORXx Complete.

Want to see what other hedge funds are holding PRPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ProPhase Labs, Inc. (NASDAQ:PRPH).

Receive News & Stock Ratings for ProPhase Labs Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProPhase Labs Inc. and related stocks with our FREE daily email newsletter.